Guardant Health推出針對實體瘤的全面免疫組化檢測Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

動脈網

05-21

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test現已提供針對所有實體瘤關鍵生物標誌物的完整IHC檢測套件，包括c-MET，此外還有...

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537593518"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537593518\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537593518?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-21 20:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537593518","market":"us","top_or_hot":-1,"title":"Guardant Health推出針對實體瘤的全面免疫組化檢測Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors","media":"動脈網","content":"<div>\n<p>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test現已提供針對所有實體瘤關鍵生物標誌物的完整IHC檢測套件，包括c-MET，此外還有...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health推出針對實體瘤的全面免疫組化檢測Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health推出針對實體瘤的全面免疫組化檢測Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-05-21 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test現已提供針對所有實體瘤關鍵生物標誌物的完整IHC檢測套件，包括c-MET，此外還有...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IHC","symbol_name":"獨立控股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b","article_id":"2537593518","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537593518","pubTimestamp":1747831920,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test現已提供針對所有實體瘤關鍵生物標誌物的完整IHC檢測套件，包括c-MET，此外還有Guardant360組織多組學分析測試。IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors .IHC測試是一種特殊的染色過程，可檢測組織樣本中的特定蛋白質，即腫瘤生物標誌物，這些標誌物可用於確定腫瘤的特徵並識別最合適的靶向癌症治療方法。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IHC":"独立控股","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","BK4162":"人寿与健康保险","GH":"Guardant Health Inc.","BK4588":"碎股","BK4196":"保健护理服务"},"translate_title":"Guardant Health launches comprehensive immunohistochemistry testing for solid tumors Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9,"IHC":1},"content_text":"Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test現已提供針對所有實體瘤關鍵生物標誌物的完整IHC檢測套件，包括c-MET，此外還有Guardant360組織多組學分析測試。PALO ALTO, Calif.--(BUSINESS WIRE)--加利福尼亞州帕洛阿爾託--（BUSINESS WIRE）--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies..Guardant Health, Inc.（納斯達克代碼：GH），一家領先的精準腫瘤學公司，今日宣佈在其腫瘤分子譜測試組合中新增一整套免疫組織化學（IHC）測試。這套新測試將幫助腫瘤科醫生識別腫瘤亞型，併為癌症患者匹配最有效的靶向療法。IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors (such as lung, breast, gastric and ovarian cancers).IHC測試是一種特殊的染色過程，可檢測組織樣本中的特定蛋白質，即腫瘤生物標誌物，這些標誌物可用於確定腫瘤的特徵並識別最合適的靶向癌症治療方法。新的Guardant IHC測試套件為所有實體瘤（如肺癌、乳腺癌、胃癌和卵巢癌）的關鍵生物標誌物提供了全面的檢測。This includes c-MET, the target of Emrelis™ (telisotuzumab vedotin-tllv), an antibody-drug conjugate recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of c-MET-expressing non-squamous non-small cell lung cancer (NSCLC)..這包括c-MET，即Emrelis™（telisotuzumab vedotin-tllv）的靶點，這是一種最近獲得美國食品和藥物管理局（FDA）批准用於治療表達c-MET的非鱗狀非小細胞肺癌（NSCLC）的抗體藥物偶聯物。“The information about tumor characteristics garnered from advanced IHC testing will complement the multidimensional insights we are currently providing to oncologists through our recently introduced Guardant360 Tissue multiomic tumor profiling test,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.“通過先進的IHC測試獲得的腫瘤特徵信息將對我們最近推出的Guardant360 Tissue多組學腫瘤分析測試所提供的多維度洞察形成補充，”Guardant Health董事長兼聯合首席執行官Helmy Eltoukhy表示。“This expansion of our portfolio will allow us to offer cancer care teams more comprehensive tissue testing capabilities through a single source to help them make more informed decisions about therapy selection and optimize outcomes for their patients.”.“此次產品組合的擴展將使我們能夠通過單一渠道為癌症治療團隊提供更全面的組織檢測能力，幫助他們做出更明智的治療選擇決策，並優化患者的治療效果。”The comprehensive IHC menu covers the following biomarkers: HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.全面的IHC菜單涵蓋以下生物標誌物：HER2、MMR、PD-L1、c-MET、ER、PR、Ki-67、CLDN18和FOLR1。About Guardant Health關於Guardant HealthGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.Guardant Health是一家領先的精準腫瘤學公司，專注於守護健康，讓每個人擁有更多免受癌症困擾的時間。自2012年成立以來，Guardant通過其先進的血液和組織檢測、真實世界數據以及人工智能分析，為疾病驅動因素提供關鍵見解，從而改變患者護理並加速新的癌症治療方法的發展。Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on .Guardant測試有助於改善整個護理階段的治療效果，包括早期癌症篩查、早期癌症復發監測以及晚期癌症患者的治療選擇。欲瞭解更多信息，請訪問guardanthealth.com並關注該公司。LinkedIn領英,，X (Twitter)X（推特）and和FacebookFacebook.。Forward-Looking Statements前瞻性聲明This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.本新聞稿包含聯邦證券法意義上的前瞻性聲明，包括關於 Guardant Health 液體活檢測試或檢測方法的潛在用途、價值、益處和優勢的聲明，這些聲明涉及風險和不確定性，可能導致實際結果與這些前瞻性聲明中表達的預期結果和期望存在重大差異。These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter.這些聲明基於當前的預期、預測和假設，由於諸多因素，實際結果可能與這些聲明存在重大差異。可能導致Guardant Health的財務和經營結果受到影響，並導致實際結果與本新聞稿中所作出的前瞻性聲明存在重大差異的其他風險和不確定性，包括在其截至2024年12月31日年度的Form 10-K年報中“風險因素”和“管理層對財務狀況及經營結果的討論與分析”標題下以及其他部分討論的內容，以及其後向證券交易委員會提交或遞交的其他報告中所述內容。The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.本新聞稿中的前瞻性陳述基於Guardant Health截至本日可獲得的信息，Guardant Health拒絕承擔更新任何前瞻性陳述的義務，以反映其預期的任何變化或事件、條件或情況的任何變化，除非法律要求。These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release..這些前瞻性陳述不應被視為代表Guardant Health在本新聞稿發佈日期之後的任何日期的觀點。Investor Contact:投資者聯繫方式：Zarak Khurshid扎拉克·赫爾希德investors@guardanthealth.com投資者@守護健康.comMedia Contact:媒體聯繫人：Michael Weist邁克爾·魏斯特press@guardanthealth.compress@guardanthealth.com+1 317-371-0035+1 317-371-0035Source: Guardant Health, Inc.來源：Guardant Health, Inc.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}